2005 Clinical Trials Data Medicine 
Cannabis Law Report
APRIL 8, 2022
as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. published the first edition of the MAPS Bulletin , titled “ MDMA Can Become a Legal Medicine ,” and the FDA rejected the second MDMA study protocol submitted by MAPS. Rick Doblin, Ph.D.,
Cannabis Law Report
OCTOBER 29, 2019
The PK data on cats shows there are differences in absorption between cats and dogs and that dosing may be different between these two species and that our chew form is likely to be more absorbable than oils in general. This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
NOVEMBER 24, 2021
Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. Focusing on professional medical publications, this study sought to investigate how medicinal cannabis is being represented in professional medical publications. The precis is simple. Background. Conclusions. Background.
Greencamp
FEBRUARY 2, 2019
Cannabis as medicine against HIV. Even though scientific data is still somewhat scarce on this topic, several studies confirm that cannabis directly acts on the cells of the immune system affected by HIV. But I haven’t seen any clinical trials looking at the direct effects of THC on the virus. 2016 ( 3 ).
Cannabis Law Report
JUNE 10, 2021
Studies of crash or driving data suggest that, although permissive marijuana policies are associated with higher prevalence of tetrahydrocannabinol (THC) presence among drivers [ 1 , 2 ], there is mixed evidence that these policies are associated with motor vehicle crashes [ 3 , 4 , 5 , 6 , 7 , 8 , 9 ]. never vs. at least once). (2)
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. No hepatic side effects were noted.
CannaMD
OCTOBER 7, 2019
In 2011, researchers published cross-sectional data from two population-based surveys including over 50,000 respondents. For instance, in a 2005 review of 297 medical charts, the Journal of Addictive Diseases reported that the rate of cannabis use in the last 12 months was lower in obese subjects than in subjects with a lower BMI.
Expert insights. Personalized for you.
52 
Let's personalize your content